Search research articles
Contact Us
Filters
Showing results (1-10 of 96) with videos related to
Page
of 10
Sort By:
Blood
|
December 28, 2018
Imaging in multiple myeloma: How? When?
Elena Zamagni, Paola Tacchetti, Michele Cavo
Hemasphere
|
March 21, 2022
Front-line treatment of multiple myeloma
Michele Cavo, Paola Tacchetti, Elena Zamagni
Lancet (London, England)
|
June 7, 2021
Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma
Michele Cavo, Paola Tacchetti, Elena Zamagni
Expert Review of Hematology
|
March 28, 2018
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
Elena Zamagni, Paola Tacchetti, Lucia Pantani, et al.
Expert Review of Anticancer Therapy
|
March 4, 2014
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations
Annamaria Brioli, Paola Tacchetti, Elena Zamagni, et al.
Journal of Clinical Medicine
|
November 4, 2020
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
Elena Zamagni, Paola Tacchetti, Simona Barbato, et al.
Cancers
|
July 13, 2024
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
Paola Tacchetti, Simona Barbato, Katia Mancuso, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
January 3, 2015
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma
Enrica Borsi, Carolina Terragna, Annamaria Brioli, et al.
Seminars in Thrombosis and Hemostasis
|
April 2, 2011
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
Elena Zamagni, Annamaria Brioli, Paola Tacchetti, et al.
Expert Opinion on Biological Therapy
|
December 9, 2024
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
Katia Mancuso, Simona Barbato, Marco Talarico, et al.
Page
of 10
Search research articles
Search
Showing results (1-10 of 96) with videos related to
Sort By:
Page
of 10
Blood
|
December 28, 2018
Imaging in multiple myeloma: How? When?
Elena Zamagni, Paola Tacchetti, Michele Cavo
Hemasphere
|
March 21, 2022
Front-line treatment of multiple myeloma
Michele Cavo, Paola Tacchetti, Elena Zamagni
Lancet (London, England)
|
June 7, 2021
Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma
Michele Cavo, Paola Tacchetti, Elena Zamagni
Expert Review of Hematology
|
March 28, 2018
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
Elena Zamagni, Paola Tacchetti, Lucia Pantani, et al.
Expert Review of Anticancer Therapy
|
March 4, 2014
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations
Annamaria Brioli, Paola Tacchetti, Elena Zamagni, et al.
Journal of Clinical Medicine
|
November 4, 2020
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
Elena Zamagni, Paola Tacchetti, Simona Barbato, et al.
Cancers
|
July 13, 2024
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
Paola Tacchetti, Simona Barbato, Katia Mancuso, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
January 3, 2015
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma
Enrica Borsi, Carolina Terragna, Annamaria Brioli, et al.
Seminars in Thrombosis and Hemostasis
|
April 2, 2011
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
Elena Zamagni, Annamaria Brioli, Paola Tacchetti, et al.
Expert Opinion on Biological Therapy
|
December 9, 2024
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
Katia Mancuso, Simona Barbato, Marco Talarico, et al.
Page
of 10